Morgan Stanley Raises Cardinal Health Price Target to $306
Morgan Stanley analyst Erin Wright has maintained a Buy rating on Cardinal Health and increased the price target to $306.
Stocks · News reference
Top Wall Street Forecasters Revamp Cardinal Health Expectations Ahead Of Q1 Earnings
Cardinal Health expects Q1 EPS of $2.94 and revenue of $66.51B. Analysts remain bullish, raising price targets up to $295.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
RBC Raises Price Target on Cardinal Health to $295 From $276
RBC Capital Markets has increased its price target for Cardinal Health, Inc. while maintaining an Outperform rating.
Evercore ISI Group Maintains Outperform on Cardinal Health, Raises Price Target to $320
Analysts Update Ratings and Price Targets for Cardinal Health
Several financial analysts updated their ratings and price targets for Cardinal Health on November 6, 2026, with targets ranging from $270 to $305.
Cardinal Health Sees Healthy Demand, Despite Modest Commodity Pressure
Cardinal Health tops Q1 2027 estimates, and raises guidance, as robust pharma sales offset petroleum headwinds in medical distribution.
Nasdaq Tumbles 4.5%; Cardinal Health Shares Gain After Upbeat Q1 Earnings
U.S. stocks tumbled: Nasdaq -4.5%, S&P 500 -3.3%, Dow -2.5%. Cardinal Health rose on strong results; AppLovin surged 32%, while Veracyte fell 55%.